https://www.jnj.com/rss-feed/all.rss RSS feed all en-US Fri, 25 Sep 2026 11:41:08 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-tremfya-guselkumab-is-the-first-and-only-il-23-inhibitor-to-show-significant-improvement-in-spinal-pain-and-stiffness-in-landmark-axial-psoriatic-arthritis-psa-study · Topline results show TREMFYA met the primary and major secondary endpoints of axial involvement in PsA - including spinal pain and stiffness - and demonstrated significant improvement in MRI-confirmed inflammation · First-ever study to use objective MRI assessments to confirm presence of axial involvement and demonstrate axial inflammation reduction in PsA Fri, 25 Sep 2026 11:41:08 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-tremfya-guselkumab-is-the-first-and-only-il-23-inhibitor-to-show-significant-improvement-in-spinal-pain-and-stiffness-in-landmark-axial-psoriatic-arthritis-psa-study https://www.jnj.com/media-center/press-releases/single-infusion-of-carvykti-ciltacabtagene-autoleucel-delivered-five-year-treatment-free-remissions-in-50-of-patients-in-early-line-relapsed-refractory-multiple-myeloma · New results suggest earlier treatment may increase the likelihood of long-term remission · Study adds to Johnson & Johnson's overwhelming body of evidence supporting its innovative multiple myeloma therapies in second line, where earlier intervention may increase long-term remission and disease control Fri, 25 Sep 2026 11:17:30 GMT https://www.jnj.com/media-center/press-releases/single-infusion-of-carvykti-ciltacabtagene-autoleucel-delivered-five-year-treatment-free-remissions-in-50-of-patients-in-early-line-relapsed-refractory-multiple-myeloma https://www.jnj.com/media-center/press-releases/new-model-based-analysis-further-supports-the-potential-of-tecvayli-teclistamab-cqyv-plus-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-to-redefine-long-term-survival-expectations-in-early-line-relapsed-refractory-multiple-myeloma · Analysis shows ~87% of patients treated with TECVAYLI® plus DARZALEX FASPRO® as early as second line were estimated to have comparable mortality risk to the general population · A separate analysis shows the survival benefit was driven by a 90% reduction in the risk of multiple myeloma progression versus standard of care, with no significant difference in rates of non-relapse mortality · Johnson & Johnson is advancing a differentiated multiple myeloma portfolio designed to deliver deeper, more durable disease control and improve long-term outcomes for patients Wed, 23 Sep 2026 14:12:59 GMT https://www.jnj.com/media-center/press-releases/new-model-based-analysis-further-supports-the-potential-of-tecvayli-teclistamab-cqyv-plus-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-to-redefine-long-term-survival-expectations-in-early-line-relapsed-refractory-multiple-myeloma https://www.jnj.com/media-center/press-releases/depuy-synthes-showcases-next-generation-trauma-innovations-at-ota-2026 New innovations across fracture fixation, connected care, AI-assisted surgery and procedural solutions reinforce the company's leadership in trauma care. Tue, 22 Sep 2026 12:07:33 GMT https://www.jnj.com/media-center/press-releases/depuy-synthes-showcases-next-generation-trauma-innovations-at-ota-2026 https://www.jnj.com/media-center/press-releases/caplyta-lumateperone-shows-significant-and-rapid-improvement-in-bipolar-mania-in-pivotal-phase-3-study CAPLYTA® significantly reduced the signs and symptoms of acute manic episodes associated with bipolar I disorder as early as Day 3, with benefits sustained through Week 3 Results build on the established efficacy, safety and tolerability profile of CAPLYTA®, further supporting its potential to reach more patients across bipolar I and II disorders Mon, 21 Sep 2026 13:45:12 GMT https://www.jnj.com/media-center/press-releases/caplyta-lumateperone-shows-significant-and-rapid-improvement-in-bipolar-mania-in-pivotal-phase-3-study https://www.jnj.com/media-center/press-releases/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-plus-lazcluze-lazertinib-with-prophylactic-strategies-shows-low-rates-of-treatment-related-events-at-wclc-2026 Low rates of rash, blood clots and administration-related reactions were observed with subcutaneous treatment and prophylaxis Fewer than 1% of patients discontinued treatment due to treatment-related events at one year New findings from Johnson & Johnson build on the MARIPOSA survival benefit and strengthen evidence for RYBREVANT FASPRO plus LAZCLUZE as first-line treatment Tue, 15 Sep 2026 12:30:00 GMT https://www.jnj.com/media-center/press-releases/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-plus-lazcluze-lazertinib-with-prophylactic-strategies-shows-low-rates-of-treatment-related-events-at-wclc-2026 https://www.jnj.com/media-center/press-releases/johnson-johnsons-2026-oncology-care-index-finds-community-oncologists-confident-in-ais-promise-but-practical-adoption-still-lags • Reported AI adoption in oncology has increased from 19% of healthcare providers across all practice settings in 2025 to 49% of community oncologists specifically in 2026 • Meanwhile use of advanced tools like predictive models remains low, at just 19%, revealing a gap between adoption and deeper implementation Mon, 14 Sep 2026 20:15:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnsons-2026-oncology-care-index-finds-community-oncologists-confident-in-ais-promise-but-practical-adoption-still-lags https://www.jnj.com/media-center/press-releases/johnson-johnsons-rybrevant-amivantamab-vmjw-plus-chemotherapy-delivers-longest-reported-median-overall-survival-in-egfr-exon-20-insertion-mutation-positive-lung-cancer RYBREVANT plus chemotherapy demonstrates durable benefit with a differentiated approach that dual-targets EGFR and MET Results mark significant progress for a patient population with poor outcomes and a historical five-year survival rate of just 8% Mon, 14 Sep 2026 12:30:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnsons-rybrevant-amivantamab-vmjw-plus-chemotherapy-delivers-longest-reported-median-overall-survival-in-egfr-exon-20-insertion-mutation-positive-lung-cancer https://www.jnj.com/media-center/press-releases/new-overall-survival-data-and-treatment-experience-improvements-reinforce-the-impact-of-rybrevant-amivantamab-vmjw-based-regimens-in-egfr-mutated-lung-cancer-at-wclc-2026 Presidential Symposium to feature final overall survival results for first-line RYBREVANT plus chemotherapy in EGFR exon 20 insertion-mutated NSCLC Additional findings show low rates of key treatment-related events with subcutaneous RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) and prophylactic strategies Fri, 11 Sep 2026 21:00:00 GMT https://www.jnj.com/media-center/press-releases/new-overall-survival-data-and-treatment-experience-improvements-reinforce-the-impact-of-rybrevant-amivantamab-vmjw-based-regimens-in-egfr-mutated-lung-cancer-at-wclc-2026 https://www.jnj.com/media-center/press-releases/johnson-johnson-receives-ce-marking-for-acuvue-oasys-max-reusable-contact-lenses New 2-week reusable contact lens brings advanced ACUVUE OASYS MAX technologies to deliver superior comfort and visual clarity to patients, even at day 14*†i Expands the ACUVUE OASYS MAX portfolio with an advanced option for reusable contact lens wearers Designed to meet the growing demand for lasting comfort and clear vision in today’s screen-intensive world *†1 Thu, 10 Sep 2026 11:45:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-receives-ce-marking-for-acuvue-oasys-max-reusable-contact-lenses https://www.jnj.com/media-center/press-releases/johnson-johnson-presents-new-data-at-ims-2026-highlighting-its-industry-leading-multiple-myeloma-portfolio-with-the-goal-of-advancing-the-potential-for-cure · 35+ abstracts demonstrate new findings across DARZALEX®, TECVAYLI® plus DARZALEX FASPRO®, CARVYKTI®, TALVEY®, and the investigational trispecific antibody ramantamig, highlighting the potential of early intervention with immune-based therapies to transform outcomes across the patient journey · With decades of leadership in multiple myeloma, Johnson & Johnson continues to drive innovation throughout the patient journey, from market-leading backbone therapies to next-generation immune-based approaches Wed, 09 Sep 2026 12:30:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-presents-new-data-at-ims-2026-highlighting-its-industry-leading-multiple-myeloma-portfolio-with-the-goal-of-advancing-the-potential-for-cure https://www.jnj.com/media-center/press-releases/johnson-johnson-spotlights-new-neuropsychiatry-data-across-bipolar-mania-depression-and-schizophrenia-at-psych-congress-2026 First presentation of pivotal Phase 3 CAPLYTA® data in adults with bipolar mania underscores the asset’s potential across mood disorders New SPRAVATO® analyses and schizophrenia research emphasize a focus on complex, high-burden neuropsychiatric conditions Tue, 08 Sep 2026 12:00:07 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-spotlights-new-neuropsychiatry-data-across-bipolar-mania-depression-and-schizophrenia-at-psych-congress-2026 https://www.jnj.com/media-center/press-releases/johnson-johnson-to-participate-in-the-deutsche-bank-2026-healthcare-summit Wed, 02 Sep 2026 20:07:36 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-to-participate-in-the-deutsche-bank-2026-healthcare-summit https://www.jnj.com/media-center/press-releases/johnson-johnson-host-investor-conference-call-on-third-quarter-results Mon, 31 Aug 2026 21:02:23 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-host-investor-conference-call-on-third-quarter-results https://www.jnj.com/media-center/press-releases/fda-approves-imaavy-nipocalimab-aahu-as-first-ever-treatment-for-warm-autoimmune-hemolytic-anemia-waiha-representing-a-landmark-advancement-for-patients · IMAAVY is an immunoselective FcRn blocker designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies while also preserving B-cell function · Warm autoimmune hemolytic anemia is a rare, life-threatening disease in which autoantibodies cause the destruction of red blood cells, leading to severe anemia and debilitating fatigue · The approval is based on the pivotal Phase 2/3 study which demonstrated durable hemoglobin responsea · A mean increase in hemoglobin of 1 g/dL at Week 1b and improvement in FACIT-Fatiguec score at Week 24 were observed in IMAAVY-treated patientsd Mon, 24 Aug 2026 22:26:56 GMT https://www.jnj.com/media-center/press-releases/fda-approves-imaavy-nipocalimab-aahu-as-first-ever-treatment-for-warm-autoimmune-hemolytic-anemia-waiha-representing-a-landmark-advancement-for-patients https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-new-global-classification-system-for-surgical-outcomes Peer-reviewed DISH Classification System establishes a standardized approach to reporting dehiscence, infection, seroma and hematoma across surgical specialties Mon, 24 Aug 2026 12:00:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-new-global-classification-system-for-surgical-outcomes https://www.jnj.com/media-center/press-releases/johnson-johnson-publishes-new-future-of-digital-surgery-report-to-help-define-the-emerging-field-of-surgical-intelligence Drawing on insights from leaders across healthcare, technology, policy and investment, the report introduces a common framework for surgical intelligence and outlines the foundations required to operationalize it responsibly at scale. Tue, 18 Aug 2026 12:30:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-publishes-new-future-of-digital-surgery-report-to-help-define-the-emerging-field-of-surgical-intelligence https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-monarch-quest-3-advancing-the-latest-in-robotically-assisted-bronchoscopy Introducing MONARCH™ QUEST 3, the latest software update for the MONARCH™ Platform, designed to enhance planning, navigation, and targeting in the early detection of lung cancer1-3. Mon, 17 Aug 2026 12:30:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-monarch-quest-3-advancing-the-latest-in-robotically-assisted-bronchoscopy https://www.jnj.com/media-center/press-releases/johnson-johnson-to-participate-in-the-morgan-stanley-24th-annual-global-healthcare-conference Mon, 10 Aug 2026 20:27:25 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-to-participate-in-the-morgan-stanley-24th-annual-global-healthcare-conference https://www.jnj.com/media-center/press-releases/johnson-johnson-to-participate-in-the-2026-wells-fargo-healthcare-conference Tue, 04 Aug 2026 20:05:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-to-participate-in-the-2026-wells-fargo-healthcare-conference https://www.jnj.com/media-center/press-releases/johnson-johnsons-executive-vice-president-jennifer-taubert-to-retire-tom-cavanaugh-appointed-evp-worldwide-chairman-innovative-medicine-effective-september Tue, 04 Aug 2026 12:46:17 GMT https://www.jnj.com/media-center/press-releases/johnson-johnsons-executive-vice-president-jennifer-taubert-to-retire-tom-cavanaugh-appointed-evp-worldwide-chairman-innovative-medicine-effective-september https://www.jnj.com/media-center/press-releases/johnson-johnsons-rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-receives-u-s-fda-priority-review-as-potential-first-in-class-egfr-and-met-targeted-subcutaneous-treatment-for-advanced-head-and-neck-cancer Priority Review reinforces the significant potential of subcutaneous amivantamab in recurrent or metastatic head and neck cancer, where the current five-year survival rate is only 15 percent Patients achieved rapid, deep and durable responses, including a 42 percent overall response rate with one-third achieving a complete response Subcutaneous amivantamab is the only therapy in head and neck cancer engineered to target both EGFR and MET, proven drivers of tumor growth and treatment resistance Thu, 30 Jul 2026 12:30:03 GMT https://www.jnj.com/media-center/press-releases/johnson-johnsons-rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-receives-u-s-fda-priority-review-as-potential-first-in-class-egfr-and-met-targeted-subcutaneous-treatment-for-advanced-head-and-neck-cancer https://www.jnj.com/media-center/press-releases/johnson-johnson-completes-acquisition-of-firefly-bio-inc-to-advance-next-generation-oncology-innovation Wed, 29 Jul 2026 21:42:41 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-completes-acquisition-of-firefly-bio-inc-to-advance-next-generation-oncology-innovation https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-collaboration-with-sail-biomedicines-to-advance-in-vivo-car-t-programs-and-transform-autoimmune-disease-through-immune-reset Wed, 29 Jul 2026 21:28:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-collaboration-with-sail-biomedicines-to-advance-in-vivo-car-t-programs-and-transform-autoimmune-disease-through-immune-reset https://www.jnj.com/media-center/press-releases/johnson-johnson-introduces-monarch-platform-to-the-middle-east The launch of the first robotically-assisted bronchoscopy platform in the market offers new options for diagnosis and treatment of early-stage lung cancer First cases also mark the first clinical use of MONARCH™ QUEST AI-enabled navigation in the region. Tue, 28 Jul 2026 12:51:21 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-introduces-monarch-platform-to-the-middle-east